- Home
- JXG vs HOTH Comparison
JXG vs HOTH Comparison
Compare JXG & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- HOTH
- Stock Information
- Founded
- JXG N/A
- HOTH 2017
- Country
- JXG China
- HOTH United States
- Employees
- JXG N/A
- HOTH N/A
- Industry
- JXG
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- HOTH Health Care
- Exchange
- JXG Nasdaq
- HOTH Nasdaq
- Market Cap
- JXG 5.2M
- HOTH 4.9M
- IPO Year
- JXG N/A
- HOTH 2019
- Fundamental
- Price
- JXG $2.58
- HOTH $1.47
- Analyst Decision
- JXG
- HOTH Strong Buy
- Analyst Count
- JXG 0
- HOTH 4
- Target Price
- JXG N/A
- HOTH $4.75
- AVG Volume (30 Days)
- JXG 73.9K
- HOTH 25.7M
- Earning Date
- JXG 12-06-2024
- HOTH 11-12-2024
- Dividend Yield
- JXG N/A
- HOTH N/A
- EPS Growth
- JXG N/A
- HOTH N/A
- EPS
- JXG 2.20
- HOTH N/A
- Revenue
- JXG $38,490,872.00
- HOTH N/A
- Revenue This Year
- JXG N/A
- HOTH N/A
- Revenue Next Year
- JXG N/A
- HOTH N/A
- P/E Ratio
- JXG $1.14
- HOTH N/A
- Revenue Growth
- JXG N/A
- HOTH N/A
- 52 Week Low
- JXG $0.75
- HOTH $0.58
- 52 Week High
- JXG $8.51
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- HOTH 57.08
- Support Level
- JXG N/A
- HOTH $1.32
- Resistance Level
- JXG N/A
- HOTH $1.71
- Average True Range (ATR)
- JXG 0.00
- HOTH 0.47
- MACD
- JXG 0.00
- HOTH -0.01
- Stochastic Oscillator
- JXG 0.00
- HOTH 23.86
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc, formerly JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.